SynthesisFrontiers in public health2026
Whole brain radiotherapy for brain metastases in Nigeria: a systematic review.
Synthesis in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Whole brain radiotherapy (WBRT) remains the most commonly used treatment for brain metastases in Nigeria due to limited access to advanced radiotherapy techniques. However, evidence on its outcomes within the Nigerian context has not been systematically summarized. Methods: A PRISMA-guided systematic review was conducted to identify studies reporting the use of WBRT for brain metastases in Nigeria by systematic searching of PubMed/Medline, Google Scholar, Embase, and Ajol. Data were extracted on study characteristics, primary tumor profiles, treatment protocols, clinical outcomes, Karnofsky and WHO performance status, and toxicities. Results Four: studies were included in this review, involving a total of 142 patients, with 128 females accounting for 90.1% of the sample size. The mean age was 47.3 ± 12.4 years. CT scan accounts for 70.6% of investigation modalities, MRI (23.5%), Both (5.9%). Mean KPS is 50, breast Cancer accounts for 82.4% of the source of metastases, 66.7% of primary tumors are in stage 3. Multiple metastatic lesions are seen in 85.9% of cases, while 76.9% of cases are supratentorial. Steroid (35%), surgery (9%), and chemotherapy (3%) are additional therapies received. Median survival period ranges between 3 to 18 months with a pooled median survival period of 3.6 months (95% CI: 2.8, 4.4), complete clinical response is seen in 53.8% of patients, with whole brain radiotherapy and improvements in WHO performance status following therapy. Conclusion: WBRT continues to provide symptomatic benefit for patients with brain metastases in Nigeria, but is limited by modest survival outcomes and gaps in outcome reporting. Improved access to advanced radiotherapy techniques and standardized reporting are needed to optimize care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.